Pfizer's $7.3B Metsera Deal Aims to Trim Lilly & Novo’s Lead in Obesity Race
Pfizer is acquiring weight-loss drug developer Metsera in a deal valued at up to $7.3 billion as it tries to catch up in the booming obesity treatment market.
More Videos
Inside the Explosive Case Accusing Social Media of Harming Kids
Maria Curi, tech policy reporter at Axios, breaks down Meta’s landmark trial as Zuckerberg testifies in a case that could reshape tech accountability.
McGraw Hill Posts Strong Q3 Growth Amid Digital and AI Push
Bob Sallmann, CFO of McGraw Hill, breaks down the quarter’s standout performance, digital expansion, and how AI tools are driving education innovation.
Starfighters Space’s Tim Franta on Rockets, Supersonic Flights, And Market Edge
Franta explains what sets Starfighters Space apart from competitors and how the company is shaping the next generation of spaceflight.
BREAKING NEWS: Supreme Court Drops Bombshell, Trump’s Tariffs Ruled Illegal In Stunning Decision
Daniel Desrochers, International Trade Reporter at POLITICO, joins us to break down the ruling, the billions at stake, and what it means for consumers.
Go Fund Yourself: The New Neurotech Frontier
NeuralAI Technologies' talks about its neuromorphic hardware powering next-gen AI applications. Plus, how High Frequency Highway is using AI for well-being.
Before You Clean Out the Garage, Watch This: Mike Wolfe on Turning Nostalgia Into Profit
Mike Wolfe previews 'History’s Greatest Picks', shares what’s driving the collectibles boom, and reveals why your old items could be worth a fortune.
